Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296035 · ClinicalTrials.gov registry record · Phase 2
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01296035: Clinical Trial Phase 2 study, sponsored by Women and Infants Hospital of Rhode Island.
NCT01296035 is a Phase 2 study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01296035, a Phase 2 study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
Primary Outcome
Documentation of known measurable or evaluable disease parameters after every 2 cycles of treatment. If any patient is withdrawn for the study prior to completion of therapy a repeat evaluation will be done at that time.
Interventions
- BIOLOGICAL Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Why NCT01296035 stopped before completion
NCT01296035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Panitumumab is the first listed.
NCT01296035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01296035 about?
NCT01296035 is a clinical study titled "Panitumumab and Gemcitabine in Relapsed Ovarian Cancer". This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
What is the current status of trial NCT01296035?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01296035?
The interventions under investigation include: Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01296035?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01296035's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia